Fund of the week: Water Street Healthcare Partners
What is Water Street Healthcare Partners?
Water Street Healthcare Partners is a Chicago-based private equity firm focused exclusively on the healthcare industry. It was founded in 2005 by Tim Dugan alongside Jim Connelly, the former president and chief operating officer of Caremark International, and Kip Kirkpatrick.
All three had previously led healthcare investments at One Equity Partners, the private equity arm of JP Morgan Chase. They left to build a single-sector vehicle dedicated to healthcare buyouts and platform-building.
The firm describes itself as a strategic investor rather than a passive financial buyer. Its model is to acquire middle-market healthcare businesses, often as carve-outs from larger corporations, and to build them into platforms through a combination of organic growth and tuck-in acquisitions.
It does not invest in biotechnology, traditional healthcare facilities such as hospitals or nursing homes, or early-stage companies without positive cash flow. Transactions typically range from $50 million to $500 million in enterprise value.
As of May 2026, the firm manages approximately $7.5 billion of equity capital across six funds. The most recent vehicle, Water Street Healthcare Partners VI, closed at its $1.9 billion hard cap on May 13, 2026, oversubscribed and completed at a first and final closing.
Water Street is a control-oriented healthcare buyout firm with a thesis built around three sectors: medical products and diagnostics, pharmaceutical and life sciences, and healthcare services.
For a royalty investor, Water Street's pharmaceutical exposure is concentrated in specialty pharma products (notably the founded-and-controlled Long Grove Pharmaceuticals), pharmaceutical services (CRO, market access, contract development), and partnered product development through its Capstone Development Services platform.
This piece looks at who Water Street is, who funds it, what its portfolio looks like, and what its royalty-relevant exposure looks like.
Overview and investment focus
Water Street's investment thesis rests on four operational propositions.
First, that single-sector specialisation in healthcare produces better deal selection and portfolio support than generalist private equity. The firm has invested exclusively in healthcare for two decades.
Second, that healthcare buyouts benefit disproportionately from operator-led decision-making. Water Street's team blends investment professionals with executives drawn from healthcare operating roles, and the firm's senior advisors include former CEOs and division heads from major pharmaceutical, medical device, and healthcare services companies.
Third, that mid-market healthcare assets are best built into platforms through buy-and-build strategies. The firm has completed more than 180 investments and acquisitions to build 48+ companies since inception, which implies an average of roughly four tuck-in acquisitions per platform.
Fourth, that corporate carve-outs from larger healthcare companies are a structurally undersupplied entry point. Water Street has historically partnered with global healthcare companies including Medtronic, Gentiva Health Services, and Matria Healthcare to take non-core divisions private and rebuild them as standalone businesses.
The portfolio spans three exposure profiles.
Healthcare services exposure includes companies like Pillr Health (hospital pharmacy enablement), MedSpeed (healthcare logistics), and historically Premise Health (employer-sponsored direct healthcare, exited to OMERS in 2018).
Medical products and diagnostics exposure spans interventional devices, lab equipment, and specialty distribution, including Alcor Scientific, Pathnostics, enableCV, and Viant Medical.
Pharmaceutical and life sciences exposure includes Long Grove Pharmaceuticals (founded by Water Street in 2019 as a complex generic injectables platform), Solvias (Swiss CMC and bioanalytical services, co-owned with JLL Partners since 2020), The Access Group (commercialisation and market access services), and historically Discovery Life Sciences (biospecimen and genomics services).
Background and formation
Water Street was founded in 2005 by Tim Dugan, Jim Connelly, and Kip Kirkpatrick, the healthcare team that had previously led investments at One Equity Partners.
Connelly's background as president and COO of Caremark International gave the new firm a senior operating profile at launch. Dugan's experience at One Equity and earlier at First Chicago Venture Capital gave the firm institutional investment infrastructure from day one.
The firm operates as a single-sector vehicle. In 2005 most healthcare-focused PE firms were either generalist platforms with a healthcare practice or specialty firms focused on a single sub-sector. Water Street positioned itself as a multi-sub-sector healthcare specialist, with the firm-level concentration spread across services, products, and pharma services rather than concentrated in any one of them.
Fund I closed in 2006. The firm has since raised five additional funds, with the dollar trajectory below.
| Fund | Year of close | Size | Notes |
|---|---|---|---|
| Fund I | 2006 | ~$370M | First independent fund after One Equity team spin-out |
| Fund II | 2008 | $650M | Closed above $600M target |
| Fund III | 2014 | ~$750M | |
| Fund IV | 2017 | $860M | |
| Fund V | 2022 | $1.4B | |
| Fund VI | May 2026 | $1.9B | Oversubscribed, closed at hard cap, first and final close |
Fund VI's first-and-final close at $1.9 billion with no further investor capacity was completed in six months in a healthcare private equity fundraising environment that has tightened materially since 2022.
Limited partners and funder base
Water Street does not publish its LP base. Several LPs have disclosed commitments through their own reporting and the firm files Form ADV in the United States.
PitchBook's Fund V profile lists at least six identifiable LPs, including the Danish pension fund AkademikerPension (commitment dated April 21, 2022). Fund IV's profile lists seven LPs including Adams Street Partners, the fund-of-funds manager.
The visible LP base across vintages includes institutional fund-of-funds, US public and corporate pension plans, and European institutional investors.
Likely LP categories, with disclosed examples where available:
| LP category | Examples / basis |
|---|---|
| US fund-of-funds | Adams Street Partners (disclosed in Fund IV) |
| European pension capital | AkademikerPension (disclosed in Fund V) |
| US public pension plans | Inferred from typical mid-market healthcare buyout LP composition |
| US corporate pension and insurance | Inferred from same |
| Endowments and foundations | Inferred from typical $1B+ mid-market US buyout LP composition |
| Family offices | Inferred from typical mid-market US buyout LP composition |
The firm has not published net IRR or DPI data for any vintage, and final close numbers for Fund I and Fund III are not consistently available in the public record.
Portfolio of investments
The public portfolio is organised by current and past companies and by the three sector groupings. The list spans more than 40 active and exited platforms.
Selected positions of particular relevance to the royalty, BD, and pharma services audience:
| Company | Sector | Notes |
|---|---|---|
| Long Grove Pharmaceuticals | Pharma products | Founded by Water Street in 2019 as complex generic injectables and topicals platform; part of Capstone Development Services |
| Solvias | Pharma services | Swiss CMC, bioanalytical, and pharma manufacturing services; acquired with JLL Partners in 2020; serves 600+ biotech and pharma customers |
| The Access Group | Pharma services | Commercialisation services platform; expanded through acquisitions of Alliance Life Sciences and Health Strategies Group in 2017 |
| Discovery Life Sciences | Pharma services | Biospecimen and genomics services for biotech, pharma, and diagnostics; Water Street acquired and exited |
| Pathnostics | Diagnostics | Molecular diagnostics, particularly UTI multiplex PCR |
| Alcor Scientific | Medical products | Specialty diagnostic instruments and consumables |
| enableCV | Medical products | Cardiovascular interventional products |
| Viant Medical | Medical products | Contract medical device design and manufacturing |
| Premise Health | Healthcare services | Employer direct healthcare; exited to OMERS Private Equity in 2018 |
| Pillr Health | Healthcare services | Hospital pharmacy enablement; acquired from Renovus Capital Partners in January 2026 |
| MedSpeed | Healthcare services | Healthcare logistics; invested August 2024 |
| Performance Health | Healthcare services | Rehabilitation products; exited March 2026 |
According to PitchBook, Water Street has completed approximately 32 exits across its six funds, the most recent being Performance Health on March 9, 2026.
Royalty stack analysis
Water Street does not own equity positions in companies that out-license therapeutic assets to large pharma for royalty streams. Royalty-relevant exposure inside the portfolio comes through three channels, each with its own economic structure.
Channel 1: Long Grove Pharmaceuticals (complex generics, owned products)
Structure. Long Grove was founded by Water Street in 2019 as a wholly owned platform to develop and commercialise complex generic injectables and topicals.
Economic profile. Long Grove operates under the 505(b)(2) and ANDA regulatory pathways, focusing on generic development opportunities with complex formulations, challenging manufacturing, supply chain constraints, and uncommon regulatory approval requirements.
Royalty stack visible to outside investors. This is conventional specialty pharma economics rather than a stacked royalty structure. Long Grove owns its products and supply chain. Where it in-licenses commercial rights to existing products, as it did with the Akorn-originated AK-FLUOR fluorescein injection, there is an upstream royalty or supply payment to the licensor, but these arrangements are not publicly disclosed in detail.
Capstone Development Services relationship. Long Grove is described as part of Capstone Development Services, a Water Street-built platform that has been developing products in partnership with pharmaceutical and medical device organisations since 2013.
The Capstone model develops branded and generic products on a partnered basis with healthcare companies. Some Long Grove products may carry contractual milestone or royalty obligations to upstream partners, although these terms are not publicly disclosed.
Royalty buyer view. Long Grove is a specialty generic pharma platform with a focus on hospital injectables. Its royalty stack is partly visible (the in-licensed products) and partly opaque (the Capstone-originated partnered products).
Channel 2: Solvias (CMC and analytical services)
Structure. Solvias is a Switzerland-based contract research, development, and manufacturing services company. Water Street and JLL Partners acquired it in June 2020.
Economic profile. Solvias generates revenue from testing, analytical, and specialised pharmaceutical manufacturing services for more than 600 biotech, medical device, cosmetic, and multinational pharmaceutical companies. It is fee-for-service revenue, not royalty revenue.
Position in the pharma value chain. Solvias is positioned in the CMC and bioanalytical chain that supports clinical-stage and commercial-stage biopharma products. Its customer list includes companies whose downstream commercial revenue will produce royalty streams for upstream IP holders. Solvias itself does not capture royalty economics on those products.
Royalty buyer view. Not a direct royalty target.
Channel 3: The Access Group / commercialisation services
Structure. The Access Group is a commercialisation and market access services platform that Water Street has expanded through tuck-in acquisitions including Alliance Life Sciences and Health Strategies Group in 2017.
Economic profile. Fee-for-service revenue from pharmaceutical and biotech clients on pricing analytics, market access intelligence, outsourced contract and revenue management, and customised research.
Royalty buyer view. Not a royalty target. Fee-for-service revenue rather than royalty revenue.
Summary: Water Street royalty stack relevance
| Channel | Royalty-stack relevance | Buyer interest |
|---|---|---|
| Long Grove Pharmaceuticals | Indirect (in-licensed products, Capstone partnered programs) | Product-level cash flows |
| Solvias | None directly | Supply chain indicator |
| The Access Group | None directly | Commercialisation indicator |
| Discovery Life Sciences | None directly | Service correlation with clinical-stage biopharma |
| All other portfolio companies | None | Not therapeutics-related |
Leadership
| Person | Role | Background |
|---|---|---|
| Tim Dugan | Founder, Managing Partner | Co-founder; previously founding partner at One Equity Partners; First Chicago Venture Capital; MBA, Chicago Booth |
| Jim Connelly | Co-founder | Former President and COO of Caremark International; co-founded firm in 2005 |
| Kip Kirkpatrick | Co-founder | Former One Equity Partners healthcare team |
| Joseph C. Papa | Operating Partner | Former CEO of Bausch + Lomb and Perrigo Company plc; joined Water Street in 2023 to source specialty pharmaceutical investments |
| David M. Johnston, Ph.D. | Operating Partner | Former President of PPD (Thermo Fisher CRO); former SVP and global head of clinical trials at LabCorp; joined in 2025 |
| Multiple Partners and Principals | Investment team | 21 partners and 9 principals across the firm per Tracxn |
PPD was a top-three global CRO before its Thermo Fisher acquisition, and Johnston led companion diagnostic development at LabCorp.
Joseph Papa's track record includes CEO roles at Bausch + Lomb and Perrigo, and earlier involvement in the launch of Celebrex.
Blue Team: the case for Water Street Healthcare Partners
Two decades of focused execution in a single sector. Water Street has invested exclusively in healthcare since 2005, completed more than 180 transactions, and built more than 48 platform companies.
The firm raised Fund VI at hard cap in six months in May 2026, with no further investor capacity accepted.
Hard-cap, first-and-final close on Fund VI. Fund VI's first and final close at $1.9 billion in May 2026 was completed in six months.
Most healthcare buyout funds raising in the 2024-2026 cycle have required multiple closes and extended fundraising timelines.
Operator-heavy team. The senior team includes Joseph Papa, former Bausch + Lomb and Perrigo CEO, and David Johnston, former PPD president, alongside the founding partners.
Both bring direct CEO-level experience in pharma services and specialty pharma.
Corporate carve-out track record. Water Street has historically partnered with global healthcare companies including Medtronic, Gentiva, and Matria to take non-core divisions private and rebuild them.
The firm has institutional knowledge of how to structure carve-out transactions, manage transition services agreements, and rebuild standalone operating capability.
Disciplined sector boundaries. Water Street explicitly excludes biotechnology, hospitals, nursing homes, and early-stage companies from its investable universe.
The firm concentrates capital in sectors where it has demonstrated operating expertise.
Specialty generics platform in a shortage-prone sector. Long Grove Pharmaceuticals operates in the complex injectable generic space, which has experienced persistent drug shortages.
Water Street built Long Grove from scratch in 2019 rather than acquiring an existing platform.
Red Team: the case against Water Street Healthcare Partners
No exposure to the royalty-bearing therapeutics market. Water Street's portfolio does not generate out-licensed therapeutic assets, does not produce milestone or royalty streams that royalty funds can monetise, and is not a counterparty to royalty market participants.
The firm's pharma services and specialty pharma exposure is commercial-stage and operating-cash-flow-driven, not licensing-driven.
LP transparency is partial. The firm has not published net IRR, DPI, or RVPI data for any vintage.
The visible LP disclosures via PitchBook capture only six identified LPs for Fund V and seven for Fund IV, far short of the full LP base.
Single-sector concentration risk. Single-sector discipline can also concentrate risk.
A healthcare policy shock, a reimbursement environment shift, or a regulatory change that affects mid-market commercial healthcare disproportionately would compress Water Street's portfolio across multiple vintages simultaneously. A generalist PE firm with a healthcare practice has diversification options that Water Street does not.
Long Grove is unproven at a meaningful exit scale. Long Grove began shipping its first products in mid-2022 and has built an injectable generics portfolio through 2025-2026, but it has not yet produced a disclosed exit.
The complex generic injectables sector has historically traded at attractive multiples to strategic buyers (e.g. Hikma, Hospira before its Pfizer acquisition, Fresenius Kabi), but a successful Long Grove exit would require either a strategic premium or a sponsor-to-sponsor secondary in a category where mid-market secondary buyer appetite has been uneven.
Solvias sits in a narrower exit market than US CDMO peers. Solvias is a Swiss bioanalytical and CDMO services company. Exit options for European CDMOs in 2025-2026 are narrower than for comparable US assets.
Strategic buyers like Lonza, Catalent (now Novo Holdings-owned), and WuXi AppTec have either captive build-out programs or face geopolitical constraints. The Swiss-specific exit path is real but narrower than a comparable US-listed CDMO would offer.
Key person concentration on the founding generation. The firm's public profile remains shaped substantially by Tim Dugan.
The multi-generation succession case has not yet been publicly tested at the managing-partner level.
Performance Health exit is fresh and lightly disclosed. The March 2026 Performance Health exit is the most recent disclosed realisation. Financial terms and the buyer have not been published in the public record.
Implications for the pharmaceutical royalty and biotech capital markets
For a royalty fund, Water Street's portfolio does not produce out-licensed therapeutic assets and does not generate royalty streams that royalty funds would underwrite. The relevant exposure is through the pharma services portfolio.
Water Street's ownership of Solvias, The Access Group, and historically Discovery Life Sciences makes it a counterparty for royalty-fund portfolio companies that consume CMC, bioanalytical, market access, or biospecimen services.
For a BD executive at large pharma, Water Street is a buyer or partner in commercial-stage healthcare services and specialty pharma carve-out transactions. The firm has partnered with Medtronic, Gentiva, and Matria for divestitures historically.
For a technology transfer office, Water Street's exclusion of biotechnology and early-stage companies means it does not absorb academic IP through licensing or NewCo formation.
Recent developments (2024 to May 2026)
| Date | Event |
|---|---|
| August 2024 | Water Street invests in MedSpeed, healthcare logistics platform |
| April 2025 | David Johnston joins as operating partner, bringing PPD and LabCorp CRO experience |
| 2025 | Pillr Health acquired from Renovus Capital Partners (announced January 2026) |
| January 14, 2026 | Pillr Health acquisition publicly announced |
| January 21, 2026 | Globalmed Logistix investment |
| March 9, 2026 | Performance Health exit |
| May 13, 2026 | Fund VI closes at $1.9 billion hard cap, oversubscribed, first and final close |
Conclusion
Water Street Healthcare Partners is a single-sector mid-market healthcare buyout firm with $7.5 billion of equity capital, six funds spanning two decades, and an operator-heavy team building platforms in healthcare services, medical products, pharma services, and specialty pharma.
Fund VI closed at $1.9 billion hard cap in May 2026, first-and-final and oversubscribed. The senior operating team has added Joseph Papa and David Johnston in 2023 and 2025.
A blue team reading the firm sees a sector specialist with two decades of track record, a recent oversubscribed fundraise, and a bench of senior operators executing buy-and-build in mid-market healthcare.
A red team reading the same firm sees opaque vintage performance disclosure, an unproven Long Grove exit case, a Swiss CDMO exit market narrower than US peers, single-sector concentration risk, and a generational succession question that has not yet been publicly tested.
Both readings are defensible from the public record.
For commercial capital markets focused on the royalty market specifically, Water Street's portfolio activity tracks mid-market commercial healthcare deal flow rather than producing royalty-bearing therapeutic assets. The firm sits on a different competitive map than Royalty Pharma, HealthCare Royalty Partners, or DRI Healthcare Trust.
All information in this article was accurate as of May 2026 and is derived from publicly available sources including Water Street Healthcare Partners' own website and press releases, regulatory and trade publications, and financial news reporting. Information may have changed since publication. This content is for informational purposes only and does not constitute investment, legal, or financial advice. The author is not a lawyer or financial adviser.